Pustular Psoriasis - 17 Studies Found Recruiting : A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis : Generalized Pustular Psoriasis Erythrodermic Psoriasis : 2017-01-13 : Drug: risankizumab risankizumab administered by subcutaneous injection. Completed : Immune Signature of Palmoplantar Pustulosis : Palmoplantar Pustulosis : 2013-01-29 Recruiting : An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis : Palmoplantar Pustulosis : 2015-12-14 : Drug: Guselkumab Participants Active, not recruiting : Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) : Generalized Pustular Psoriasis (GPP) Adalimumab : 2015-08-20 : Drug: Adalimumab Adalimumab Terminated : Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis : Palmo-Plantar Pustular Psoriasis Palmo-Plantar Pustulosis : 2010-03-18 : Drug: Ustekinumab Patients ran Completed : Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) : Psoriasis : 2013-09-24 : Biological: Secukinumab Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg Active, not recruiting : An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis : Pustular Psoriasis : 2015-01-16 : Drug: Guselkumab Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and Recruiting : BI655130 Single Dose in Generalized Pustular Psoriasis : Psoriasis : 2016-11-29 : Drug: BI655130 Completed : A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis : Palmoplantaris Pustulosis : 2006-07-14 : Drug: Placebo comparator Patie Recruiting : A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis : Moderate to Severe Psoriasis Generalized Pustular Psoriasis and : 2017-02-09 : Other: Placebo Next >>>
